Investigational drug · Phase 3
Dotinurad
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gout, Tophaceous Gout.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
23
Any phase or sponsor naming "Dotinurad"
First trial start
2025
Aug 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dotinurad", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Gout
- Tophaceous Gout
Approved drugs for the same conditions: Gout
Largest trials
Live from ClinicalTrials.gov: studies naming "Dotinurad" as an intervention, largest first.
- A Study of Dotinurad Versus Allopurinol in Participants With GoutPivotal-lookingRecruiting
Crystalys TherapeuticsIndustry
NCT07089875 · 500 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 29, 2027
Drug: Allopurinol; Dotinurad · For: Gout
Sites: Birmingham, Alabama; Foley, Alabama; Gilbert, Arizona · 122 sites in all
- A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With GoutPivotal-lookingCompleted
Eisai Co., Ltd.Eisai
NCT05007392 · 451 participants · Start Dec 21, 2021 · Primary completion Jun 14, 2023
Drug: Dotinurad; Febuxostat · For: Gout
Sites: Hefei, China; Beijing, China; Foshan, China · 30 sites in all
- Effect of Dotinurad in Hyperuricemia With HypertensionPivotal-lookingRecruiting
Saga UniversityAcademic, hospital or other
NCT06834230 · 360 participants (planned) · Start Mar 28, 2025 · Primary completion Jul 31, 2027
Drug: Dotinurad; Febuxostat · For: Hyperuricemia or Gout; Hypertension
Sites: Saga, Japan
- Study of FYU-981 in Hyperuricemia With or Without GoutPivotal-lookingCompleted
Fuji Yakuhin Co., Ltd.Industry
NCT03006445 · 330 participants · Start Dec 2016 · Primary completion Aug 23, 2018
Drug: FYU-981 · For: Hyperuricemia With or Without Gout
Sites: Tokyo, Japan
- A Study of Dotinurad Versus Allopurinol in Tophaceous GoutPivotal-lookingRecruiting
Crystalys TherapeuticsIndustry
NCT07089888 · 250 participants (planned) · Start Aug 4, 2025 · Primary completion Dec 31, 2027
Drug: Allopurinol; Dotinurad · For: Tophaceous Gout
Sites: Birmingham, Alabama; Foley, Alabama; Gilbert, Arizona · 99 sites in all
- Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without GoutPivotal-lookingCompleted
Mochida Pharmaceutical Company, Ltd.Industry
NCT03372200 · 203 participants · Start Jan 9, 2018 · Primary completion Jun 4, 2018
Drug: FYU-981; Febuxostat · For: Hyperuricemia With or Without Gout
Sites: Tokyo, Japan
- Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without GoutPivotal-lookingCompleted
Fuji Yakuhin Co., Ltd.Industry
NCT03100318 · 201 participants · Start Apr 1, 2017 · Primary completion Apr 25, 2018
Drug: FYU-981; Benzbromarone · For: Hyperuricemia With or Without Gout
Sites: Tokyo, Japan
- Study of FYU-981 in Hyperuricemia With or Without GoutPivotal-lookingCompleted
Fuji Yakuhin Co., Ltd.Industry
NCT02416167 · 200 participants (planned) · Start May 2015 · Primary completion May 2016
Drug: FYU-981; Placebo · For: Hyperuricemia
Sites: Tokyo and Other Japanese City, Japan
- The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution TimePivotal-lookingNot yet recruiting
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT07661030 · 142 participants (planned) · Start Jul 30, 2026 · Primary completion Jul 30, 2027
Drug: Dotinurad; colchicine and 1 more · For: Gout
Crystalys TherapeuticsIndustry
NCT07535034 · 90 participants (planned) · Start May 8, 2026 · Primary completion Jul 2027
Drug: Dotinurad · For: Gout
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 41 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Changes in kidney function during dotinurad treatment for hyperuricemia: a systematic review.
Tongu Y, Wakutsu T, Sakai W, et al. · Clin Exp Nephrol 2026
- Urate-Lowering Effect of Dotinurad During Concomitant Sodium-Glucose Cotransporter 2 Inhibitor Therapy for Chronic Kidney Disease: A Retrospective Study.
Habuka M, Otsuka S, Satokata K, et al. · J Clin Med Res 2026
- The Human Urate Transportosome: Evolutionary Dynamics, Molecular Mechanisms, and Pharmacogenetic Perspectives.
Dzhemileva LU, D'yakonov VA, Marshala SN, et al. · Med Sci (Basel) 2026
- Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis.
Yi G, Huang X, Huang Y, et al. · Drugs Real World Outcomes 2026
- URAT1 inhibition in hyperuricemia and gout: from transporter biology to clinical precision therapy.
Li G, Wang Y, Zhang Z · Front Immunol 2026
- Safety profiles of two XOD and two URAT1 inhibitors in hyperuricemic patients: a real-world pharmacovigilance analysis based on the FAERS and JADER databases.
Shi W, Huang X, Zhao X, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
Also in development for Gout
- AR882Phase 33 trials
Arthrosi Therapeutics · Gout, Hyperuricemia, Gout Chronic
- TigulixostatIBI128, LC350189Phase 33 trials
Innovent Biologics Technology Limited (Shanghai R&D Center) · Gout, Hyperuricemia, Gout Flare
- ABP-671Phase 32 trials
Atom Therapeutics Co., Ltd · Chronic Kidney Disease, Gout
- PRX-115Phase 21 trial
Protalix · Gout
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.